ERBB2 and triple-negative breast carcinoma: For instance, the introduction of the anti-HER2-targeted therapy trastuzumab has significantly enhanced survival rates of patients with HER2-positive breast cancer (Romond et al., 2005), which was previously comparable to that of patients with triple-negative breast cancer.